The Smallpox Threat: A Time to Reconsider Global Policy

Abstract

Get full access to this article

View all access options for this article.

References

World Health Organization. Smallpox Eradication: Destruction of Variola Virus Stocks. WHA document 64.11. Geneva: World Health Organization; 2011.

Henderson

. Smallpox virus destruction and the implications of a new vaccine. Biosecur Bioterror, 2011; 9(2):163-168.

Arita

. The Smallpox Eradication Saga. Hyderabad, India: Orient Blackswan; 2010:16-20.

World Health Organization. Final Report of the Global Commission for the Certification of Smallpox Eradication. Geneva: World Health Organization; 1980.

Tucker

. Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur Bioterror, 2011; 9:1-13.

World Health Organization. Advisory Committee on Variola Virus Research. Report of the Twelfth Meeting. Geneva: World Health Organization; 2013.

World Health Organization. Advisory Group of Independent Experts to Review the Smallpox Research Programme (AGIES). Geneva: World Health Organization; 2013.

World Health Organization. Scientific Review of Variola Virus Research 1999-2010. Geneva: World Health Organization; 2010.

Alibek

, Handelman

. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. New York: Random House; 1999.

10.

World Health Organization. Working Document: Mechanisms for Acquisition and Release of Smallpox Vaccine by WHO. Geneva: World Health Organization; 2004.

11.

Kennedy

, Gurwith

, Dekker

, et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naïve adults. J Infect Dis, 2011; 204:1395-1402.

12.

World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization 2013. Conclusions and Recommendations. Wkly Epidemiol Rec, 2014; 89:1-2.

13.

Ruepp

. European Medicines Agency Activities on Smallpox. Paper prepared for the WHO Advisory Committee on Variola Virus Research, September 2013.

14.

European Medicines Agency, Committee for Medicinal Products for Human Use. Assessment Report: IMVANEX. Procedure No. EMEA/H?C/002596. London: European Medicines Agency; 2013.

15.

Hatch

, Graham

, Bewley

, et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol, 2013; 87:7805-7815.